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ABSTRACT
Prostaglandins are anticancer agents known to
inhibit tumor cell proliferation both in vitro and
in vivo by affecting the mRNA stability. Here we
report that a MAR-binding protein SMAR1 is a target
of Prostaglandin A2 (PGA2) induced growth arrest.
We identify a regulatory mechanism leading to
stabilization of SMAR1 transcript. Our results show
that a minor stem and loop structure present in the
5’ UTR of SMAR1 (r1-UTR) is critical for nucleopro-
tein complex formation that leads to SMAR1 stabi-
lization in response to PGA2. This results in an
increased SMAR1 transcript and altered protein
levels, that in turn causes downregulation of Cyclin
D1 gene, essential for G1/S phase transition. We
also provide evidence for the presence of a variant
5’ UTR SMAR1 (r17-UTR) in breast cancer-derived
cell lines. This form lacks the minor stem and
loop structure required for mRNA stabilization in
response to PGA2. As a consequence of this, there
is a low level of endogenous tumor suppressor
protein SMAR1 in breast cancer-derived cell lines.
Our studies provide a mechanistic insight into the
regulation of tumor suppressor protein SMAR1 by
a cancer therapeutic PGA2, that leads to repression
of Cyclin D1 gene.
INTRODUCTION
Most of the cellular transformation processes often
involve changes in the gene expression levels rather than
changes in the sequence itself. The multiple layers of
control include a closely knit transcriptional program
and the associated translation of the product.
Posttranscriptional regulation (includes mRNA stability
and translation) is one such mechanism whereby the
organisms control the ﬂow of genetic information into the
proteome (1). Within the continuum of posttranscrip-
tional regulation, mRNA stability is considered a major
eﬀector of gene regulation (2). For example, the levels of
several cell cycle regulatory molecules like Cyclin D1, p21,
p27 and cdks are known to oscillate from a high in
dividing cells to a low in quiescent cells. Most of these
oscillations are due to transcriptional control and
regulated protein stability (3). The manifestation of
cancer is a consequence of the loss of control of one or
more of these regulations that leads to a loss of gene
function. Anticancer drugs like ﬂavopiridol and cyclopen-
tenone prostaglandins (PGs) are potent inhibitors of cell
cycle in various cell lines (4–6). These compounds cause
growth arrest in cultured cells and exhibit antitumor
activity in vivo primarily by aﬀecting cell cycle regulatory
molecules. Cyclopentenone PGA1 and ﬂavopiridol are
shown to aﬀect the transcriptional rate of Cyclin D1 and
levels of cdk4 (7,8). PGA2-mediated growth inhibition is
attributed to the downregulation of Cyclin D1 by
reduction in the mRNA transcript. Further, microarray-
based studies have led to the identiﬁcation of mRNA
species whose transcription and/or steady-state levels are
regulated by cyclopentenone PGs (9–11). A number of
reports have also documented the role of some RNA-
binding proteins such as ELAV family proteins or TIA-1
and TIAR that bind to the 50 or 30 UTR of cell cycle
regulatory molecules and lead to an increased/decreased
mRNA expression upon PGA2 treatment (12,13).
Recently, we have reported that SMAR1 (Scaﬀold/
Matrix attachment region-binding protein 1) is a tumor
suppressor MAR-binding protein that downregulates
Cyclin D1 expression by recruiting HDAC1-mSin3A
co-repressor complex at Cyclin D1 promoter locus (14).
SMAR1 is documented to be a tumor suppressor protein
that interacts with p53 (15) and retards B16F-10-induced
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criptional repressor for MARb-mediated transcription
from Eb locus, governing V(D)J recombination in T cells.
Transgenic mice overexpressing SMAR1 exhibits lym-
phoid organomegaly, associated with higher inﬁltration
of lymphoid cells (17). Further, a drastic downregulation
of SMAR1 in higher grades of breast cancer and cancer-
derived cell lines like MCF-7, HBL-100, ZR 75.3 and
ZR 75.1 has also been observed. (14,18).
In the present study, we looked for a possible reason for
downregulation of SMAR1 in breast cancer-derived cell
lines and a therapeutic agent to restore SMAR1 levels. We
ﬁnd that the stability of SMAR1 mRNA in MCF-7 cells is
low and treatment of this cell line with antitumor agent
PGA2 increases the stability of the transcript. The increase
in SMAR1 mRNA stability is attributed to a 18bp stem
and loop structure of SMAR1 50 UTR (f1-UTR) that
serves as a cognition site for binding of regulatory
proteins, essential for conferring transcript stability.
Interestingly, we identify a variant of SMAR1 50 UTR
(f17-UTR) that lacks the stem and loop structure of f1,
leading to an altered stability. Moreover, we ﬁnd that the
expression of f17-UTR, correlated to an elevated Cyclin
D1 level marks the malignant nature of these breast
cancer-derived cell lines. Additionally, the involvement of
SMAR1 in PGA2-mediated growth arrest underscores the
importance of regulation of such tumor suppressor genes
by anticancer agents like PGA2.
MATERIALS AND METHODS
Cell cultureand transient transfections
MCF-7 cells were maintained in DMEM supplemented
with 10% fetal calf serum (Invitrogen) in presence of 5%
CO2 at 378C. Cells were seeded at a density of 1 10
6 per
35mm dish and cultured for 24h before transfection.
MCF-7 cells were treated with PGA2 at various concen-
trations in fresh complete medium. Cells were harvested
24h after PGA2 treatment. Actinomycin D (Sigma) was
used at a concentration of 4mg/ml and incubated for
indicated time points.
Semi-quantitative RT–PCR
Seven micrograms of total RNA was subjected to reverse
transcription in 20ml reaction mixture containing 1 
random hexanucleotide mix, 1mM dNTPs, RNase
inhibitor and MuMLV reverse transcriptase (Invitrogen).
PCR reactions were carried out in a 25ml reaction mixture
using 1ml cDNA as template. Gene-speciﬁc primers used
are listed in Table 1.
RealTime RT–PCR
The quantitative measurements of RNA transcripts was
performed by icycler iQ thermal cycler system (BioRad)
using double-stranded DNA-speciﬁc ﬂurophore SYBR
Green. In a 25ml PCR reaction, 1ml of cDNA was
ampliﬁed using 1  iQ SYBR Green Supermix (BioRad)
containing 0.4mM dNTP mix, 1.5mM MgCl2, 50pmol of
forward and reverse primer mix, SYBR Green I, 0.5U
iTaq DNA polymerase. Resolution of the product of
interest from nonspeciﬁc ampliﬁcation was achieved by
melt curve analysis. Quantitation was done with three
diﬀerent sets of cDNA samples. Sigma plot was used for
statistical analysis and plotting graphs.
Cloning ofr1and r17 UTR
The f1 and f17 UTRs were PCR ampliﬁed using speciﬁc
primers from f1 and f17 templates, described previously
(19). The PCR products were then cloned in and PGEM-T
Easy for f1 and TOPO-TA vector for f17. Plasmids
isolated from positive colonies were digested with EcoR1
and cloned in pEGFP vector.
RNase protection assay(RPA)
To determine the half-life of SMAR1, Actinomycin D at a
ﬁnal concentration of 4mg/ml was added to MCF-7 cells.
For stability assays, PGA2 (70mM) and Actinomycin D
were added simultaneously to the culture media.
Table 1. Diﬀerent sets of primers and oligos used for assays
Figure Primer/Oligo Product
1A and B, 2C, D,
5B ,C
For-AGACAAACACCACGAGAAT
Rev-CGGAGTTCAGGGTGATGAGTGTGAC
SMAR1 (Predominantly
f1 form)
1C, 5 B, C For-CTTCCTCTCCAAAATGCCAG Rev-AGAGATGGAAGGGGGAAAGA Cyclin D1
1, 2, 5 For-TACCACTGGCATCGTGATGGACT Rev-TTTCTGCATCCTGTCGGCAAT b-actin
2 E, G For-CGGCACGAGACAAACACCA Rev-TGCAATCTGAACCACATCCGC Composite UTR
2 F For-AGACAAACACCACGAGAAT Rev-TTCATCATCATCTCGTCACGA f1
2 F For-CAGCAGCCGCAGCCCACAC Rev-TTCATCATCATCTCGTCACGA f17
2A, B Amplicon from For-AGACAAACACCACGAGAAT
Rev-CGGAGTTCAGGGTGATGAGTGTGAC cloned in PGEM-T Easy
SMAR1 (recognizes f1 form
predominantly)
2I Amplicon from For-AGACAAACACCACGAGAAT
Rev-TTCATCATCATCTCGTCACGA cloned in PGEM-T Easy
f1 UTR
2I Amplicon from For-CAGCAGCCGCAGCCCACAC
Rev–TTCATCATCATCTCGTCACGA cloned in TOPO-TA
f17 UTR
4 D–G CGAAATTAACCCTCACTAAAGGGAACCCACGGTCGACAGAAACC SL1
4G CGAAATTAACCCTCACTAAAGGGAACCACACGGTCGACAGTGACC Mutant 1
4 G CGAAATTAACCCTCACTAAAGGGAACCACATAATCGACAGGGACC Mutant 2
5F, G For-TGAAAATGAAAGAAGATGCAGTCG,
Rev-GAAACTTGCACAGGGGTTGT
Probe II Cyclin D1 promoter
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treatment, washed in 1  PBS and pelleted at 1000r.p.m.
Total RNA was isolated using Tri-Reagent (Sigma) and
used for protection assay. Antisense RNA probes were
made by linearizing f1 and f17 SMAR1 templates using
Nco1 or Pst1, respectively and performing in vitro
transcription in the presence of SP6 or T7 RNA
polymerase, respectively. In a 25ml transcription reaction
containing 1mg of linearized DNA fragment, 1  tran-
scription buﬀer (Stratagene), 0.4mM each of ATP, CTP,
GTP, 0.25mM UTP and 50mCi [a32p] UTP (BRIT),
40U of RNasin and 20U of T7/SP6 RNA polymerase
(Stratagene) were used to label RNA. Labeled RNA
transcripts were then puriﬁed using probe quant G-50
columns (Amersham Pharmacia). Samples were heated at
908C for 3min before hybridization. For the hybridization
reaction, 10mg of total RNA was incubated with labeled
probe ( 10
5c.p.m.) in hybridization buﬀer at 378C for
16h. The reaction mixtures were then diluted using 300ml
of digestion buﬀer. Single-stranded RNA was then
digested using RNaseT1 (15mg/ml) and RNaseA (1mg/
ml) for 2h at 308C. After phenol/chloroform extraction
and ethanol precipitation, samples were analyzed on 6–
10% urea gel. Band intensities were quantiﬁed using
phosphorimager (BioRad).
RNA electrophoretic mobility shift assays (EMSAs)
PBK-CMV f1 and f17 were linearized with Xho1 and
in vitro transcribed with T3 polymerase to yield the respec-
tive 50 UTR probes. The wild-type and mutant UTR minor
stem and loop sequences were synthesized as forward and
reverse complementary oligonuceotides (Genomechanix),
containing T3 polymerase site. They were then annealed
with respective pairs and in vitro transcibed with T3
polymerase to yield theprobes. The sequences are:
SL1-Fwd: CGAAATTAACCCTCACTAAAGGGAACC
CACGGTCGACAGAAACC,
Mutant 1-Fwd: CGAAATTAACCCTCACTAAAGGG
AACCACACGGTCGACAGTGACC,
Mutant 2-Fwd: CGAAATTAACCCTCACTAAAGG
GAACCACATAATCGACAGGGACC and their reverse
complementary. EMSAs were performed in a 10ml
binding reaction containing 10mg of MCF-7 cell extract,
either untreated or treated with PGA2 and 12fmol of
transcript, 10mM Tris (pH 7.4), 15mM KCl, 5mM
MgCl2 and 10% glycerol. For competition assays, cold
competitors were mixed with the hot probe 10min prior to
incubation with lysate. All reactions were carried out on
ice for 20min and then run on 8% native gel, resolved,
dried and processed for autoradiography.
Immunoblotting and antibodies
Cells were scraped in 1  PBS, collected at various time
points and lyzed using DIGNAM buﬀer. Equal amount of
proteins were taken for immunoblotting. Following
SDS–PAGE, the resolved proteins were transferred to
PVDF membrane (Amersham). Blocking was carried out
with 5% BSA in Tris-buﬀered saline containing 0.1%
Tween-20 (TBST). The membranes were probed with
primary and respective secondary antibody. Proteins were
detected using ECL plus chemiluminescence substrate
(Amersham). Antibodies used are Cyclin D1 and Actin
(Santa Cruz). SMAR1 polyclonal antibody was raised in
house as described earlier (14). Mouse secondary HRP
and rabbit secondary HRP were purchased from BioRad.
Immunostaining
MCF-7 cells were seeded on cover slips and after 24h, the
cells were treated with indicated amount of PGA2.
Posttreatment, cells were washed with ice-cold 1  PBS
and the cells were ﬁxed with 2% PFA for 15min at room
temperature. After subsequent quenching and blocking in
PBS containing 10% FCS, SMAR1 antibody was added
onto the cover slips and incubated for an hour. After three
washes with cold PBS, cells were incubated with secondary
rabbit FITC in dark for 45min. Cells were then washed
three times with ice-cold PBS and mounted using Anti-
fade (DABCO) from Sigma. The mounted slides were then
visualized using confocal laser microscope (LSM-510,
Zeiss, Thornwood, NY).
Luciferase reporter assay
For luciferase assays, 1mg of Cyclin D1 luciferase
promoter construct (CD1) was cotransfected with f1o r
f17 SMAR1 with an internal GFP control in MCF-7
cells. Luciferase assays were performed 24h posttransfec-
tion or PGA2 treatment. For SMAR1 knockdown
experiments, 100nM siRNA was cotransfected with
Cyclin D1 promoter construct. Luciferase activity was
measured using Luclite substrate (Perkin Elmer, USA)
and assay performed using Top-Count luminometer
(Packard Life sciences, USA). Equal amounts of protein
were used for luciferase assays and relative light units
plotted for luciferase activity.
Chromatin Immunoprecipitation (ChIP) analysis
ChIP assay kit (Upstate Biotechnology) was performed
following manufacturer’s instructions. 1 10
6 cells were
plated per 30mm dish and treated with PGA2 or vehicle.
After treatment, DNA–protein complexes were ﬁxed with
1% formaldehyde at 378C for 10min at various time
points. ChIP assays were carried out using anti-SMAR1,
anti-HDAC1, anti-H3K9, anti-H4K10, RNA pol II, H3
pSer10 and H3K9 methyl antibodies (Cell Signaling).
Input DNA, rabbit IgG (r-IgG), and mouse IgG (m-IgG)
pulled DNA served as controls for all the experiments.
Immunoprecipitated DNA was then subjected to 28 cycles
of PCR using primers for probe II described earlier (14).
Cell cycle analysis
MCF-7 cells were plated at a density of 1 10
5 on a
35mm dish. After 6h of serum starvation, synchronized
cells were transfected with SMAR1 siRNA, f1o rf17
SMAR1 plasmid constructs using Lipofectamine 2000
(Invitrogen). Twelve hours posttransfection, cells were
treated with 30 and 70mM PGA2 in case of siRNA
transfection and cells were harvested 36h posttransfec-
tion. After trypsinization, cells were collected and washed
6006 Nucleic Acids Research, 2007, Vol. 35, No. 18in PBS and pelleted at 1000r.p.m. The resulting pellet was
then re-suspended in 0.2ml 1  PBS containing 2% fetal
bovine serum and ﬁxed in 0.8ml 70% ethanol. Cells were
kept in the ﬁxative for 2h and then centrifuged for 5min
at 1000r.p.m. Cells were then treated with RNase A
(75U/ml) and re-suspended in 0.5ml PBS containing
50mg/ml propidium iodide (PI) and 0.1% Triton X-100.
This was incubated at room temperature for 30min and
subjected to ﬂow cytometry. PI-stained cells were analyzed
for cell cycle proﬁles by FACS Vantage (Becton
Dickinson) using Cell Quest.
RESULTS
PGA2 induces SMAR1 expression
The negative regulation of Cyclin D1 by SMAR1 and
PGA2 are well documented, though the mechanisms
reported are diﬀerent (8,14). This prompted us to check
the interdependence of these pathways and look for a
possible regulation of SMAR1 by PGA2. To evaluate this
study, we employed MCF-7 cell line derived from
mammary epithelia that is characterized by low invasive
potential and induced Cyclin D1 level correlated
to reduced SMAR1 expression (14). MCF-7 cells were
treated either with vehicle (ethanol) or PGA2 (0–100mM).
Total RNA was isolated 24h posttreatment and the
cDNA obtained was subjected to RT–PCR and Real time
RT–PCR analysis. SMAR1 transcript levels increased
upto 45mM PGA2 treatment, after which a steady-
state level of the transcript was observed (Figure 1A).
Quantitation by Real time RT–PCR showed that SMAR1
transcript increased 1.8- to 2-fold at 30–100mM PGA2
(Figure 1B). The transcript proﬁle was normalized using
b-actin. PGA2-induced SMAR1 protein levels were
checked using western blot analysis using 30 and 70mM
PGA2. At these concentrations, the protein expression
increased by 3.8- and 4.5-fold respectively, while the
protein levels were very low in untreated and vehicle-
treated cells (Figure 1C and D). The steady increase in
the protein amounts were then visualized using confocal
microscopy. MCF-7 cells were treated with PGA2 (15, 30
and 70mM) and the protein levels were monitored using
SMAR1 antibody. A steady increase in the amount of
SMAR1 was observed from 15 to 70mM PGA2 concen-
trations (Figure 1E).
PGA2 stabilizes SMAR1 mRNA
It is well known that most of the reported prostaglandin-
mediated eﬀects occur through alteration in mRNA half-
life. Results from the previous section show that PGA2
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Figure 1. PGA2 induces SMAR1 expression. (A) MCF-7 cells were treated with vehicle (alcohol) and various concentrations of PGA2. Total RNA
was obtained from aforementioned samples and used for reverse transcription. SMAR1 and b-actin transcript levels were studied using 1ml of cDNA
in RT–PCR (B) SMAR1 transcript was quantiﬁed from the above obtained cDNA by real-time–PCR analysis. Bar graphs represent the fold changes
in the transcript after PGA2 treatment. (C) Western blot analysis of SMAR1 and b-actin was performed from PGA2-treated or vehicle-treated MCF-
7 cell extracts as indicated. (D) Densitometry analysis for protein expression of SMAR1 reveals that protein levels increase by 3.8- and 4.5-fold upon
30 and 70mM PGA2 treatments. (E) Immunostaining of MCF-7 cells using anti-SMAR1 antibody was performed upon PGA2 treatment at 15,
30 and 70mM concentrations. All the results represented indicate the average of three independent experiments.
Nucleic Acids Research, 2007, Vol. 35, No. 18 6007treatment increased SMAR1 transcript by 2-fold but the
protein level by 4-fold, indicating a possible involvement
of mRNA stability. To address this issue, half-life of
endogenous SMAR1 transcript was veriﬁed by blocking
cellular transcription using Actinomycin D (4mg/ml) and
cells were collected at indicated time points (Figure 2A).
Total RNA was isolated and subjected to RPA as
described in ‘Materials and Methods’ section. As shown
in Figure 2A upper panel, SMAR1 transcript level
decreased after 4h in Actinomycin D-treated samples.
Interestingly, upon addition of Actinomycin D and
PGA2, we observe that the levels of SMAR1 transcript
remained steady till 24h (Figure 2B, upper panel). This
indicates that PGA2 stabilizes SMAR1 mRNA and
maintains the steady-state levels of the transcript. The
mRNA available at the given time points were normalized
to the actin transcript and quantiﬁcation represented as
bar graph (Figure 2A and B).
SMAR1has two 5’UTR variants inMCF-7 cells
The stability and translation of most of the transcripts are
associated with the untranslated regions, both at 50 and 30
UTRs. Primers were designed to amplify the sequence
from the start of exon1 and a part of exon 2 that was
expected to yield an intact SMAR1 50 UTR of 142bp (18).
The amplimer of 50 UTR from the cDNA of MCF-7 cells
untreated and treated with PGA2 were checked on a 10%
polyacrylamide gel. Interestingly, untreated cells showed a
single amplimer (Figure 2C, lane 1) while in case of PGA2
treatment (30 and 70mM), there was an additional
amplimer (Figure 2C, lanes 2 and 3). The fast migrating
amplimer (lower band) was common to both untreated
and PGA2 treated cells, while there was an induction of
the slower migrating amplimer (upper band) speciﬁcally in
PGA2-treated cells. Thus, the upper and the lower bands
represent two variants of 50 UTR. Earlier, we have
reported the identiﬁcation of three clones of SMAR1
from mouse thymocyte cDNA library (19). Out of these,
two clones shared the same open reading frame and same
translational reading frame of downstream sequence, but
diﬀered only by 18 bases in 50 UTR. The two clones were
denoted as f1 (containing full-length 50 UTR) and f17
(containing variant 50 UTR lacking 18 bases). When
checked using f1 and f17 template controls (Figure 2D,
lanes 2 and 4), we ﬁnd that the size of upper band
obtained upon PGA2 treatment corresponded to the f1
form (the upper band in Figure 2C, lanes 2 and 3;
Figure 2D, lane 5) and the lower band in untreated and
PGA2-treated cells corresponds to f17 form (the lower
band in Figure 2C, lanes 1–3, Figure 2D, lane3). This was
further veriﬁed by cloning the corresponding PCR
products in PGEMT-Easy vector and DNA sequencing.
RT–PCR analysis of cDNA from MCF-7 cells (untreated
or treated with 70mM PGA2, lanes 1 and 2, respectively)
with primers speciﬁc for f1-UTR and f17-UTR forms
was performed. The results revealed that upon PGA2
treatment there was no apparent change in the f17 form
but there was an increase in the f1 form of SMAR1
(Supplementary Figure S1A). The map of SMAR1 gene
and the primers used are depicted in Supplementary
Figure S1B.
The responsiveness of5’ UTR toPGA2 is essential
forSMAR1 mRNA stability
Next we checked if the responsiveness of SMAR1 UTR to
PGA2 contributed to the stability of SMAR1 transcript.
The antisense UTR transcript speciﬁc to each form was
hybridized with the total RNA from MCF-7 cells
untreated or treated with PGA2, as described in
‘Materials and Methods’ section. Protected bands revealed
that the f17 form was predominant in untreated cells,
unlike the f1 form (almost 3–4-times lower than
f17, veriﬁed by densitometry). An increase in protection
of f1 transcript was observed upon PGA2 treatment while
f17 form remained almost unchanged (Supplementary
Figure S1C). To validate the transcript proﬁles of f1-
UTR and f17-UTR containing SMAR1, cDNA obtained
was subjected to Real time RT–PCR analysis using
primers speciﬁc to the UTRs and melt curve analysis
performed. The transcript proﬁle obtained after
Actinomycin D treatment showed that the half-life of f1
was 4–6h while that of f17 varied between 14–16h
(Figure 2E). Though the transcript level of f1 remained
stable after PGA2 and Actinomycin D treatment, f17
transcript levels started to decline from 12h, as veriﬁed by
melt curve analysis (Figure 2F). Quantiﬁcation of
transcripts revealed that f1-SMAR1 level increased
2-fold at 6h time point of PGA2 treatment and remained
steady till 24h, while there was a negligible change in
f17-SMAR1 level (Figure 2G). These results point out at
the early response of f1-UTR to PGA2 treatment that
stabilizes the transcript till 24h. To further assess the
response of the two UTRs to PGA2, we performed
reporter assays, where the UTRs from both forms were
cloned upstream of gfp gene in pEGFP vector. In case of
f1-UTR transfection, we observed a 2–3-fold increase
in GFP expression upon PGA2 treatment compared to the
untreated cells (Figure 2H, lanes 3–5). f17-UTR transfec-
tion however showed only a minor change in the basal
expression of GFP, showing that f1 and not f17 is
responsive to PGA2 (Figure 2H, lanes 7–9). Thus, we
demonstrate that in MCF-7 cells, f1 form of SMAR1 and
not f17 form responds to PGA2.
r1-UTR stem andloop structure iscritical for
PGA2-induced complex formation
The natural tendency of RNA is to form highly stable
secondary and tertiary structures and the alteration in
these structures represent a well-known regulatory
mechanism for many cellular processes (20). To determine
the diﬀerences in the secondary structure that could
implicate a functional signiﬁcance, we analyzed the f1 and
f17 UTR sequences as shown in Figure 3A. Prediction of
the secondary structures of the two UTRs was done using
M-fold secondary structure prediction software (21). After
energy minimizations, we observed that f17-UTR lacks a
small stem and loop structure, pertaining to those missing
18 bases (Figure 3B).
6008 Nucleic Acids Research, 2007, Vol. 35, No. 18Figure 2. PGA2 stabilizes SMAR1 mRNA. (A) Equal number of MCF-7 cells were seeded in 35mm dishes and 24h later treated with 4mg/ml
Actinomycin D. Cells were collected after indicated time points and total RNA isolated using Tri reagent. In case of PGA2 treatment, 70mM PGA2
was added to cells 12h prior to Actinomycin D treatment. Stabilization of SMAR1 transcript by PGA2 was veriﬁed using RPA. Antisense probe
from Nco1 digested SMAR1 fragment from PGEM-T Easy was used and protection assays were performed as described in ‘Materials and Methods’
section. Upper panel shows that the half-life of SMAR1 in MCF-7 cells is about 4h. (B) Upper panel shows protection of SMAR1 mRNA over the
indicated time intervals upon Actinomycin D and PGA2 treatment. The lower panels show actin mRNA levels used as control. The bar graphs both
in A and B represents the quantiﬁcation of transcripts normalized to actin. (C) RT–PCR analysis of cDNA from untreated and PGA2-treated MCF-
7 cells using composite UTR primers reveals the ampliﬁcation of a lower size fragment in cells (lane1) while in treated sample, the upper band
becomes prominent with increasing PGA2 concentration (lanes 2 and 3). (D) Ampliﬁcation of speciﬁc UTRs of cDNA from control and PGA2-
treated cells reveals that f17 is present in untreated cells (lane 3) and f1 in PGA2-treated samples (lane 5) as checked by ampliﬁcation with template
control (lanes 2 and 4). The pUC mix marker (Fermentas) in lane 1 was used to identify the molecular size of the fragments. (E) Quantitation of
transcript derived from f1 and f17 after Actinomycin D treatment reveals that the half-life of f1 is between 4 and 6h and that of f17 between 14
and 16h. The transcripts were normalized to b-actin control. (F) Real-time–PCR analysis of f1 and f17 transcript upon PGA2 and Actinomycin D
treatment reveals that f1 form remains constant while the f17 form does not respond to PGA2 treatment and there is a decline in the transcript
Nucleic Acids Research, 2007, Vol. 35, No. 18 6009The major factor that controls mRNA turnover is the
association of RNA-binding proteins with sequences
forming stable secondary structures. We checked for the
association of such proteins with SMAR1 UTR, in the
presence and absence of PGA2. RNA EMSA were
performed to check for putative nucleoprotein complex
formation on f1-UTR. Labeled RNA obtained by
transcription of the respective 50 UTR templates (f1 and
f17) were used to perform EMSAs. The binding reactions
were performed as described in ‘Materials and Methods’
section. The mixture was then run on 6% native gel and
subjected to autoradiography. We could detect three
speciﬁc nucleoprotein complexes on f1-UTR, in the
PGA2-treated lane alone compared to the untreated cell
lysate (Figure 4A, lanes 2 and 3). Upon addition of 50-fold
molar excess self-cold competitor, we ﬁnd a complete
abolishment of all three shifted complexes, revealing the
speciﬁcity of the complex formation (Figure 4A, lane 4).
f17-UTR however failed to form nucleoprotein complex,
indicating that the missing 18 bases holds the key
determinant to bind to certain factors that in turn
govern the stability and translation of SMAR1
(Figure 4B). To validate this, RNA was transcribed
from the f1 template encoding the stem and loop
structure (named SL1 hereafter). Using this transcript as
probe, EMSAs were performed as described earlier. SL1
also showed nucleoprotein complex formation, compar-
able to the f1-UTR upon PGA2 treatment (Figure 4D).
Further, competition experiments with 10-fold molar
excess cold competitors showed the speciﬁcity of the
complex (Figure 4E). To identify the importance of the
secondary structure imparted by the sequence, binding
assays using two mutants were performed. Mutant 2 had a
minor modiﬁcation of the primary sequence but the
secondary structure remained largely unperturbed
(where nucleotides outside boxB were modiﬁed) while in
Mutant 1, the stem–loop structure pertaining to boxB was
predicted to be partly disrupted (Figure 4C). When
compared to SL1 (Figure 4F, lane 2) both Mutant 1 and
Mutant 2 showed a reduced complex formation, although
to varying degrees. Mutant 1, where the core stem
structure was disrupted, lacked the speciﬁc complex
formation compared to Mutant 2 (Figure 4F, lanes 4
and 6, respectively). Thus, we emphasize that the
secondary structure imparted by these 18 bases to
SMAR1–UTR is critical for the complex formation.
Further, to identify the number and putative molecular
weights of the components of speciﬁc nucleoprotein
complex, UV cross-linking experiments were performed
as described in ‘Materials and Methods’ section. The
binding mixture employing SL1 from the intact UTR
as probe was subjected to UV cross-linking, resolved
on 10% SDS–PAGE gel followed by autoradiography.
After subtraction of the molecular weight of the RNA
probe ( 15kDa), we ﬁnd the involvement of three speciﬁc
proteins of  90, 40 and 15kDa in forming the ribonu-
cleoprotein complex (Figure 4G). Though the identity
of these factors remains unknown, we believe that
these factors that bind to the stem and loop structure
of UTR upon PGA2 treatment could be the key in
stabilizing the SMAR1 mRNA, resulting in altered
protein levels.
The responsiveness of5’ UTR toPGA2 is essential
forCyclin D1downregulation
Since SMAR1 is known to possess transcriptional
regulatory functions, the implication of the responsiveness
of 50 UTR to PGA2 in vivo was veriﬁed. The inverse
correlation of Cyclin D1 downregulation and SMAR1
induction was ﬁrst veriﬁed upon treatment with 30 and
70mM PGA2 (Figure 5A). The results so far suggest that
PGA2 treatment stabilizes f1mRNA, the product of
which results in Cyclin D1 repression. To conﬁrm this, we
performed luciferase reporter assays where Cyclin D1
regulation by f1 and PGA2 were compared.
Cotransfection of 0.5 and 1mgo ff1 SMAR1 along with
Cyclin D1 promoter construct (CD1-luc) revealed that f1
downregulated Cyclin D1 by 1.5- and 2.5-fold, compar-
able to PGA2-treated samples. Moreover, PGA2 treat-
ment after knockdown of SMAR1 using the speciﬁc
siRNA showed ineﬃcient downregulation of Cyclin D1
(Figure 5B). This reveals the importance of SMAR1
produced from f1 transcript in PGA2-mediated
after 16h time point. The transcripts were normalized to b-actin control. (G) Real-time–PCR analysis of f1 and f17 transcripts in PGA2-treated
MCF-7 cells reveals that the f1 form increases 1.5–2-fold between 6 and 16-h interval and thereafter remains steady till 24-h time point while f17
amount remains almost unchanged after PGA2 treatment. (H) The responsiveness of the two UTRs to PGA2 was veriﬁed using GFP reporter assay.
One microgram of each of the UTR-GFP vector was transiently transfected in separate sets of experiments, cells collected 24h posttransfection and
veriﬁed for the GFP counts after addition of PGA2 (30 and 70mM). There was a 1.8–2-fold increase in the GFP count in the f1 UTR (bars 3–5)
compared to the f17 UTR (bars 7–9) that did not show any signiﬁcant increase in GFP count. Lanes 6 and 10 represent vehicle controls with each of
the UTR plasmids. EGFP vector and ethanol were used as controls (lanes 1 and 2). Transfection of plasmids was veriﬁed using SMAR1 RT–PCR
(right panel). The bars are a depiction of three sets of experiments and error bars denote the mean SD.
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6010 Nucleic Acids Research, 2007, Vol. 35, No. 18repression of Cyclin D1. As discussed earlier, the
recruitment of SMAR1 and the associated corepressor
complex to Cyclin D1 promoter is well documented, and
hence we veriﬁed if SMAR1 occupied Cyclin D1 promoter
in response to PGA2 (Figure 5C). We observed the
interaction of HDAC1 and SMAR1 upon PGA2 treat-
ment (Supplementary Figure S2A and B). Chromatin
immunoprecipitation experiments using MCF-7 cells
either untreated or treated with 70mM PGA2 were
performed. Ampliﬁcation of probe II region in SMAR1
and HDAC1 immunoprecipitated from PGA2 treated
cells (30 and 70mM) showed the recruitment of SMAR1
corepressor complex on Cyclin D1 promoter (Figure 5D,
lanes 2 and 3, 9 and 10,). siRNA-treated, SMAR1-pulled
chromatin was used to verify the speciﬁcity of the
recruitment (Figure 5D, lanes 6 and 7, 12 and 13). These
results are consistent with the direct recruitment of
HDAC1 and SMAR1 on Cyclin D1 promoter that is
responsible for the observed repressive eﬀects. Upon over
expression, SMAR1 is shown to deacetylate the histones
at H3K9 and H4K8 loci that is accompanied by depho-
sphorylation of H3-phospho-ser 10at Cyclin D1 promoter
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15kDa (the molecular weight of  45nt RNA) from these and the correct sizes identiﬁed to be  90, 30 and 15kDa.
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control (input) for ampliﬁcation (lanes 1, 5, 8, 11 and 14). Transfection of empty vector was performed as mock control (lane 4). (E) To study the
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of SMAR1 binding to the promoter region.
6012 Nucleic Acids Research, 2007, Vol. 35, No. 18locus. Therefore, we checked if these modiﬁcations persist
upon PGA2 treatment or if any additional histone
modiﬁcations are involved in repression of Cyclin D1.
We observed a decrease in acetylation at H3K9
(Figure 5E, lanes 5 and 6), H4K8 (Figure 5E, lanes 8
and 9) and phosphorylation of H3p-ser 10 (Figure 5E,
lanes 11 and 12) in PGA2-treated cells compared to mock-
treated cells. In addition to this, H3K9 monomethylation
status that is well documented to have a role in
transcriptional activation was investigated. As shown in
Figure 5E, lanes 14 and 15, PGA2 treatment decreased the
methylation of probe II region compared to mock
treatment. To establish the repression of transcription
brought about by SMAR1, the recruitment of RNAP II
on Cyclin D1 promoter locus was studied. Decreased
ampliﬁcation of probe II region in RNAP II-pulled
samples compared to mock treated suggests decreased
transcription from Cyclin D1 promoter locus (Figure 5E,
lanes 2 and 3). Nonspeciﬁc probe III was used as negative
control (lanes 17 and 18). Mouse and rabbit IgG served as
negative controls (Figure 5D, lanes 15 and 17).
Cell cycle arrest function ofPGA2 mediated by SMAR1
depends on the 5’ UTR
Previous studies by Bhuyan et al. (22) showed that PGA2
exerts growth inhibitory activity in many human cell lines.
Consistent with this, we found that PGA2 treatment
caused G1 phase arrest by DNA content analysis using
ﬂow cytometry. We then checked if this growth inhibitory
eﬀect of PGA2 is mediated by SMAR1. Hundred-
nanomolar SMAR1 siRNA was transfected in MCF-7
cells and 16h posttransfection, PGA2 was added to the
culture media. Cell cycle analysis was done 24h post-
PGA2 treatment, after checking the knockdown of
SMAR1 (data not shown). There was a marked shift of
the cells from G1 to S and G2 phase, indicating that
PGA2 was no longer able to arrest cells in G1 phase in the
absence of SMAR1 (Figure 6A). The results so far suggest
the involvement of PGA2 in stabilizing f1 SMAR1 and it
is also clear that SMAR1 is required for PGA2-mediated
growth arrest. This prompted us to investigate the
diﬀerence in growth arrest function of SMAR1, in context
of the two UTRs it can host. For this, MCF-7 cells were
transiently transfected with equal amounts of f1o rf17-
SMAR1 and analyzed for cell cycle progression. DNA
content analysis revealed a 1.2–2.5-fold higher number of
cells in G1/S phase in case of f1-SMAR1 transfection in
comparison to f17- SMAR1 (Figure 6B). This hints
that the growth inhibitory eﬀect of PGA2 is mediated at
least partially by f1-SMAR1. To check if the PGA2-
mediated induction of SMAR1 speciﬁcally leads to
Cyclin D1 downregulation, western blot analysis to
check the status of other cyclins was performed. The
results were then veriﬁed using siRNA treatment of
SMAR1. The speciﬁcity of SMAR1 upregulation upon
PGA2 treatment was also veriﬁed using siRNA treatment
(Supplementary Figure S3A). The status of other cyclins
(Cyclin A, B and associated cyclin kinases cdks 4 and 6)
was unaltered (Supplementary Figure S3B). This result
was corroborated using cDNA microarray results
(Supplementary Figure S4).
Breast cancer-derived cell lines from mammary epithelia
primarily express f17 form
To ﬁnd out if the mechanism of downregulation of
SMAR1 by altering the mRNA stability is common to
breast cancer-derived cell lines, we screened for the
presence of the two forms of SMAR1 UTR in ZR75-1,
SKBR-3, T47D and MDA-MB-231. Diﬀerent cell lines
were cultured, RNA isolated and limited cycle RT–PCR
analysis was performed. RT–PCR analysis showed that
ZR-75-1 failed to show the product that corresponds to
f1-UTR form but expresses f17-UTR only (Figure 6C,
lane 2 upper and middle panel). This was similar to MCF-
7 cells where a very low ampliﬁcation of f1-UTR
transcript was observed (Figure 6C, lane 6, upper and
middle panel). Other cell lines like MDA-MB-231, SKBR3
and T-47D expressed the f1-UTR form predominantly
and f17-UTR form to a lower extent (Figure 6C, lanes 1,
4 and 5, upper and middle panel). HEK-293 cells, where
f1 form is expressed predominantly and f17-UTR is
undetectable was used as control (Figure 6C, lane 3, upper
and middle panels). The transcript proﬁle we have
obtained is in accordance with our previous result,
where we have observed that ZR-75-1 and MCF-7 express
very low amount of endogenous SMAR1 protein, whereas
other cell lines showed a relatively high SMAR1 expres-
sion (14). Since the UTR proﬁle of ZR-75-1 and MCF-7
cells was similar, we checked the response of this cell line
to PGA2 treatment and compared to MCF-7 cell line.
Upon 30mM PGA2 treatment, we found a signiﬁcant
induction of the f1-UTR form compared to the untreated
cells (Figure 6D, lanes 1 and 3, upper panel). This was
strikingly similar to MCF-7 cells where PGA2 treatment
leads to induction of f1-UTR form (Figure 6D, lanes 2
and 4, upper panel). Cyclin D1 proﬁles in these cell lines
untreated or treated with PGA2 showed that the repres-
sion of Cyclin D1 occurred in case of PGA2-treated
samples that correlate with the emergence of f1-UTR
form.
DISCUSSION
The primary eﬀect of hormonal therapeutics like PGA2
has been documented through alteration of half-life of
mRNA (23,24). The signiﬁcant role of mRNA stability in
gene expression makes it an essential component in
pathways whereby tissues and organs respond to stress.
Several anticancer agents like PGA2 rely on their ability to
alter the mRNA stability of target cell cycle regulatory
molecules, to govern the cell cycle fate. The essence of
mRNA stability is the balance between regulation by
destabilization determinants or translational inhibitory
structures that are rendered favorable for transcription
upon appropriate stimuli (25).
The current study stems from the fact that SMAR1
transcript is found to be drastically downregulated in
higher grades of breast cancer and breast cancer-derived
cell lines (14,18). Our aim was to decipher the reason for
Nucleic Acids Research, 2007, Vol. 35, No. 18 6013downregulation of SMAR1 in breast cancer-derived cell
lines, speciﬁcally in context to MCF-7 cell line.
Considering that both SMAR1 and PGA2 are documen-
ted to halt cell cycle at G1/S phase, it was an interesting
possibility that PGA2 regulates SMAR1, thereby bringing
about the repression of a common target gene, i.e Cyclin
D1. MCF-7 cell line is characterized by low levels of
SMAR1 transcript that is attributed to a half-life of 4h,
which in turn leads to a poor endogenous protein level.
PGA2 treatment, however, renders the transcript stable
till 24h and elevates SMAR1 level in the cell line. Since
majority of the cases involving mRNA stability rely on the
ability of the UTR present on the 50 or 30 end of the
transcript to respond to varying stimuli, the aim was to
decipher the role of SMAR1 UTR in conferring stability
to the transcript. Ampliﬁcation of the 50 UTR end of
SMAR1 lead to the identiﬁcation of a variant form of
SMAR1-UTR in MCF-7 cells. This has been previously
identiﬁed as f17-SMAR1 and possesses the same ORF
and reads out SMAR1 protein similar to the f1 clone.
SMAR1 transcript proﬁle also reveals that this form is
predominant in MCF-7 cells, contributing to almost 65%
of the observed total transcript (data not shown). The
half-life of the transcript with respect to the two UTR
forms is also diﬀerent, with f1 having a half-life of 4–6h
while that of f17 is 14–16h. Since the secondary structure
of RNA is thought to play a signiﬁcant role in imparting
stability and hence dictating the protein translation, we
analyzed the secondary structure of both the UTRs. The
f1 UTR of SMAR1 is a thermodynamically stable
structure and diﬀers from its variant form (f17) in
hosting a minor stem–loop structure, the one formed by
the missing 18 bases. Recent studies highlight the
importance of binding of regulatory proteins to diﬀerent
structures posed by the RNA (26). Further investigations
indicated that this sequence is critical for SMAR1
Figure 6. PGA2 requires SMAR1 for its growth-inhibitory function in MCF-7 cells. (A) MCF-7 cells were analyzed by ﬂow cytometry 24h post-
PGA2 treatment in the presence or absence of SMAR1 siRNA. The treatments done are indicated in the graph. The graph represents the average
percentage of cells in G1, S and G2 phase in three independent experiments and error bars denote SD. Analysis shows that in the absence of SMAR1
(knocked down by siRNA), there is a marked shift of cells from G1 to S and G2 phase. (B) MCF-7 cells transiently transfected with f1o rf17 were
collected 24h posttransfection and processed for DNA content analysis. The graph indicates that f1 retains the cell cycle arrest function while f17 is
ineﬃcient in imposing cell cycle arrest at G1/S phase. (C) RT–PCR analysis of UTR speciﬁc to f1 and f17 in diﬀerent breast cancer-derived cell
lines. Equal amount of RNA was reverse transcribed and cycling reactions performed under limiting conditions for all sets of primers as indicated.
(D) RT–PCR analysis of cDNA from ZR-75-1 and MCF-7 cells untreated (lanes 1 and 2) or treated with 30mM PGA2 (lanes 3 and 4), product
ampliﬁed using FP1-2R primers to visualize the composite UTR forms.
6014 Nucleic Acids Research, 2007, Vol. 35, No. 18stabilization brought about by nucleoprotein complex
formation on the stem–loop structure. The competition
studies using diﬀerent mutants showed that the secondary
structure of the loop was important. It is thus possible that
upon PGA2 treatment certain proteins that recognize this
fold, bind to the stem and loop structure and regulate
mRNA stability, resulting in increased SMAR1. This
could be an alternate selection mechanism in tumor cells,
whereby a variant UTR containing a transcript, encoding
a tumor suppressor protein is retained for yet other
unknown functions. Interestingly, we also ﬁnd that the
growth-inhibitory response of cells to PGA2 is in part due
to the stabilization of SMAR1 mRNA by 50 UTR, as the
knock down of SMAR1 leads to a compensation in the
growth-arrest function of PGA2. Considering that we
have identiﬁed a 50 UTR variant that is most likely a splice
variant of the full-length UTR, it is tempting to
hypothesize that RNA-binding factors involved in splicing
regulate SMAR1 mRNA stability. This possibility cannot
be ruled out as the splicing site between ﬁrst and second
exon junction of SMAR1 that spans 23kb, hosts the
18 base stem–loop structure critical for SMAR1 stabili-
zation. It is plausible that the recruitment of ribonucleo-
proteins like TIA-1 that aid in 50 UTR splicing (27) is
regulated by another stabilizing factor. This is essential for
splicing of the 60 bases from the 30 end of ﬁrst exon to 50
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Nucleic Acids Research, 2007, Vol. 35, No. 18 6015end of the second exon, to form the composite stem–loop
structure (Figure 7A). In breast cancer-derived cells,
low level of endogenous SMAR1 and subsequently high
level of Cyclin D1 leads to cell proliferation, malignant
transformation, and hence neoplasia. Under conditions
that favor proliferation or lead to malignant transforma-
tion, cancer cells might have evolved such strategies to
downregulate tumor suppressor proteins like SMAR1, as
witnessed by low levels of the protein in breast cancer-
derived cell lines. Treatment with anticancer therapeutics
that lead to cell cycle arrest, reverse this eﬀect and proteins
like SMAR1 that downregulate proliferative genes are
upregulated. It is also possible that SMAR1 transcript
stabilized by PGA2 has a deﬁnitive link with the estrogen
responsiveness of cell line, at earlier stages of transforma-
tion. In case of advanced cancer cases, however, this
posttranscriptional control mechanism might be defective.
Therefore, in spite of having f1-SMAR1 and expressing
SMAR1 protein, the existence of alternative pathways
that nullify the eﬀect of SMAR1 cannot be ruled out.
Thus, our studies provide a mechanism where a ther-
apeutic agent PGA2 used to treat malignancies, alters the
mRNA stability of tumor suppressor protein SMAR1,
that downregulates the proliferative gene Cyclin D1.
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